Taysha Gene Therapies (TSHA)
(Real Time Quote from BATS)
$2.04 USD
+0.02 (0.99%)
Updated Oct 2, 2024 03:00 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
TSHA 2.04 +0.02(0.99%)
Will TSHA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TSHA
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
Other News for TSHA
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
Taysha Gene Therapies to present on TSHA-102 in Rett Syndrome
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)